NCT01676259: An overdue trial by Silenseed Ltd
This trial is overdue. It was due to report 2 years, 1 month ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT01676259 |
|---|---|
| Title | A Prospective, Multinational, Multi-Center, Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 7, 2018 |
| Completion date | Oct. 31, 2022 |
| Required reporting date | Oct. 31, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 773 |